Generation and evaluation of a monoclonal antibody, designated MAdL, as a new specific marker for adenocarcinomas of the lung

Abstract

Background:Different therapy regimens in non-small-cell lung cancer (NSCLC) are of rising clinical importance, and therefore a clear-cut subdifferentiation is mandatory. The common immunohistochemical markers available today are well applicable for subdifferentiation, but a fraction of indistinct cases still remains, demanding upgrades of the panel by new markers.Methods:We report here the generation and evaluation of a new monoclonal antibody carrying the MAdL designation, which was raised against primary isolated human alveolar epithelial cells type 2.Results:Upon screening, one clone (MAdL) was identified as a marker for alveolar epithelial cell type II, alveolar macrophages and adenocarcinomas of the lung. In a large-scale study, this antibody, with an optimised staining procedure for formalin-fixed tissues, was then evaluated together with the established markers thyroid transcription factor-1, surfactant protein-A, pro-surfactant protein-B and napsin A in a series of 362 lung cancer specimens. The MAdL displays a high specificity (>99%) for adenocarcinomas of the lung, together with a sensitivity of 76.5%, and is capable of delivering independent additional diagnostic information to the established markers.Conclusion:We conclude that MAdL is a new specific marker for adenocarcinomas of the lung, which helps to clarify subdifferentiation in a considerable portion of NSCLCs.

The Study on Newly Developed McAb NJ001 Specific to Non-Small Cell Lung Cancer and Its Biological Characteristics

“…Additionally, tumor antigens can also provide prognostic information for the cancer patients [34] . The tumor-associated antigens of human lung cancer have been recognized for many years; however, few reports have investigated the common antigens or common epitopes of lung cancer [35] , [36] . In this study, the antigen which was finally named SP70 recognized by NJ001 was proven to be a protein with a Mr of 70 kDa.…”

The RNA/DNA‐binding protein PSF relocates to cell membrane and contributes cells' sensitivity to antitumor drug, doxorubicin

“…In addition, with the combination of the immunosuppressant cyclophosphamide and the sequential immunization of two cell types with highly similar genetic backgrounds but different phenotypes with respect to MDR potential, this approach is able to generate monoclonal antibodies capable of distinguishing cellsurface proteins that may play a functional role in MDR (11)(12)(13). Especially, the monoclonal antibodies and their immunogens generated by this approach may provide novel clinically relevant reagents and/or tools for cancer immunotherapy and diagnosis, because these antibodies normally are not commercially available (14)(15)(16).…”